The inverted pyramid of biomarker-driven trials

Abstract

In the past, clinical phase I trials often suffered from low response rates and inadequate experimental drug doses. Over the past decade, however, phase I trials have evolved from simple dose-finding studies to trials that might provide clinically relevant therapeutic opportunities for patients with advanced-stage cancer for which no standard therapies are… (More)
DOI: 10.1038/nrclinonc.2011.113

Topics

2 Figures and Tables

Slides referencing similar topics